title: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.
abstract: We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NETs).
  
  
  METHODS
  NET patients received somatostatin radiopeptide therapy with90Y-DOTATOC or177Lu-DOTATOC. The incidence of diabetes mellitus and its mortality were assessed using univariate and multivariate regression.
  
  
  RESULTS
  Overall, 1,535 NET patients were enrolled and received 3,807 treatment cycles. After treatment, 72 patients developed diabetes mellitus, including 47 cases after90Y-DOTATOC and 25 cases after combined treatment. The diabetes mellitus risk was higher before than after DOTATOC (estimate, 0.0032; P < 0.001), and overall survival was similar in patients with and without diabetes mellitus (hazard ratio, 1.13; 95% confidence interval, 0.91-1.39; n = 1,535; P = 0.27).
  
  
  CONCLUSIONS
  Radiopeptide therapy does not appear to increase the risk of developing diabetes mellitus in NET patients, whereas diabetes mellitus does not appear to increase the mortality of NET patients undergoing receptor-targeted radiopeptide therapy.
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.|Institute of Statistics, Ulm University, Ulm, Germany.
authors.forename: Maria
authors.initials: M
authors.lastname: Umlauft
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Radojewski
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
authors.forename: Petar-Marko
authors.initials: PM
authors.lastname: Spanjol
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Dumont
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.|Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Marincek
authors.affiliation: Division of Medical Oncology, University Hospital Bern, Bern, Switzerland.
authors.forename: Attila
authors.initials: A
authors.lastname: Kollar
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Philippe
authors.initials: P
authors.lastname: Brunner
authors.affiliation: Institute of Statistics, Ulm University, Ulm, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Beyersmann
authors.affiliation: Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Jan
authors.initials: J
authors.lastname: Müller-Brand
authors.affiliation: Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany; and.
authors.forename: Helmut R
authors.initials: HR
authors.lastname: Maecke
authors.affiliation: Division of Endocrinology, Diabetes & Clinical Nutrition, University Hospital Bern, Bern, Switzerland.
authors.forename: Markus
authors.initials: M
authors.lastname: Laimer
authors.affiliation: Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland m.a.walter@gmx.net.|Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Walter
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D015897:Comorbidity; D048909:Diabetes Complications / Q000401:mortality*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000401:mortality* / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015995:Prevalence; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D013557:Switzerland / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C496730:90Y-octreotide, DOTA-Tyr(3)-; C447941:lutetium Lu 177 dotatate; D015282:Octreotide
keywords: adverse event; metabolic therapy; sstr2; targeted therapy; toxicity